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Background: The effect of physical and chemical permeation enhancers on in vitro transdermal permeation of
lidocaine was investigated in the horse.
Therefore, the effect of six vehicles (phosphate-buffered saline (PBS), 50% ethanol, 50% propylene glycol, 50%
isopropylalcohol, 50% isopropylalcohol/isopropylmyristate and 50% dimethylsulfoxide) was examined as well as the
effect of microneedle pretreatment with different needle lengths on transdermal drug delivery of lidocaine.
The skin was obtained from the thorax of six Warmblood horses and was stored up to two weeks at - 20°C. Franz-type
diffusion cells were used to study the transdermal permeation through split skin (600 μm thickness). The amount of
lidocaine in the receptor fluid was determined by UV–VIS high-performance liquid chromatography.
Results: All investigated vehicle supplementations diminished the transdermal flux of lidocaine through equine skin in
comparison to pure PBS except dimethylsulfoxide, which resulted in comparable permeation rates to PBS. The
maximum flux (Jmax) was 1.6-1.8 fold lower for lidocaine applied in 50% ethanol, propylene glycol, isopropylalcohol and
isopropylalcohol/isopropylmyristate. A significant higher Jmax of lidocaine was observed when lidocaine was applied in
PBS onto microneedle pretreated skin with similar permeation rates in both needle lengths. After 6 hours, 1.7 fold
higher recovery rates were observed in the microneedle pretreated skin samples than in the untreated control samples.
The lagtimes were reduced to 20–50% in the microneedle pretreated skin samples.
Conclusion: Microneedles represent a promising tool for transdermal lidocaine application in the horse with a rapid
systemic bioavailability.
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Lidocaine (lignocaine) represents an amide local anesthetic
drug which is also systemically used as an anti-arrhythmic
drug [1]. It has recently also gained interest as systemically
used prokinetic drug in the treatment of the postoperative
ileus in horses [2-5].
Since the transdermal drug administration provides
many advantages over oral treatments or injections, the
approach of transdermal drug delivery systems has
attracted the attention of many researchers all over the
world not only in human medicine but also in veterinary
research. A topically applied drug has to overcome the* Correspondence: Jessica.stahl@tiho-hannover.de
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article, unless otherwise stated.main skin barrier, the stratum corneum, which comprises
dead corneocytes embedded in a lipid-rich domain mainly
consisting of free fatty acids, cholesterol and ceramides
[6]. Studies in humans have demonstrated the effective-
ness of topically applied lidocaine for treating chronic,
neuropathic, osteoarthritic and muscle related pain [7-12].
However, after placement of a single 5% lidocaine patch
on each fore leg of horses, no lidocaine was detected in
blood samples up to 12 hours of patch application [13].
Aside from this, after topical application of a single dose
of 0.02% lidocaine cream to horses no lidocaine was de-
tected in blood or urine samples, while it could be deter-
mined in urine samples of dogs in concentrations up to
48 ng/ml after multiple applications to canine skin [14].
The objective of the current work was, therefore, to as-
sess the impact of chemical and mechanical permeationCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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using a simple diffusion technique. First, five different
chemical additives known as permeation enhancers of
transdermal drug delivery (diemthylsulfoxide, ethanol, iso-
propylalcohol, isopropylmyristate and propylene glycol)
were investigated for their impact on transdermal lido-
caine delivery through equine skin. Second, physical pene-
tration enhancement was performed using microneedles
(200 μm and 300 μm long titanium needles) in order to
pre-treat the equine skin samples before lidocaine applica-




All chemicals used for the buffer solutions in the present
study were of the highest purity available and were pur-
chased from Merck, Darmstadt, Germany. Lidocaine
hydrochloride monohydrate and dimethylsulfoxide were
purchased from Merck as well. Ethanol was obtained from
Applichem GmbH, Darmstadt, Germany. Propylene glycol
was purchased from Riedel-de Haen, Seelze, Germany,
isopropylalcohol from Lab-Scan, Dublin, Ireland, and iso-
propylmyristate from Sigma-Aldrich, Steinheim, Germany.
Membranes
The skin was harvested from six male and female (3/3)
Warmblood horses after euthanasia in the Clinic for
Horses, University of Veterinary Medicine, Foundation,
Hannover, for reasons not related to the present study.
Thus, an ethical approval was not necessary for our study.
The skin over the thoracic region was dissected away and
was frozen at −20°C up to two weeks. The average age of
the horses was 14 years (±3 years).
In vitro permeation
The skin was defrosted at room temperature and the hair
was removed with clippers before an electrical dermatome
(Zimmer, Eschbach, Germany) was used to obtain 600 μm
thick skin slices. Franz-type diffusion cells (6G-01-00-15-
12, PermeGear, Riegelsville, PA, USA, and Gauer Glas,
Püttlingen, Germany) with a diffusion area of 1.77 cm2
and a receptor volume of approximately 12 ml were filled
with phosphate-buffered saline (PBS, pH 7.4; 1 l contains
0.2 g KCl, 8.0 g NaCl, 0.2 g KH2PO4, 1.44 g Na2HPO4 ×
2H2O and deionised water) and were maintained at 34°C
to provide 32°C skin samples. Small skin pieces (2 × 2 cm)
were incubated in PBS for 30 minutes before mounting
the skin samples with the stratum corneum side upper-
most. After baseline samples (0.4 ml) were taken from the
receptor chamber, 1 ml of each test substance solution
was applied onto the skin. The permeation of lidocaine
out of each test solution was examined in duplicate per
animal, while six horses were investigated in total. Samplesfrom the receptor chamber were taken at predefined times
up to 6 hours or 22 hours.
Experimental setup
To investigate the effect of different vehicles on lidocaine
permeation, the following vehicles were used (2 mg/ml
lidocaine): PBS, ethanol (50% in PBS w/w; EtOH), propyl-
ene glycol (50% in PBS w/w; PG), isopropylalcohol (50% in
PBS w/w; IPA), isopropylalcohol/isopropylmyristate (50%
in PBS w/w; IPM/IPA), and dimethylsulfoxide (50% in
PBS w/w; DMSO). Furthermore, the effect of microneedle
pretreatment on transdermal drug delivery of lidocaine
was investigated using two microneedle rollers (Medik8,
London, United Kingdom) with different needle lengths
(200 μm and 300 μm), both of which possessed of 192 ti-
tanium needles in a cylindrical arrangement (diameter of
150 μm at the basis). The microneedle pretreatment was
performed after an incubation phase in PBS for 30 minutes
using skin samples which were placed on a styropor panel
and fixed with needles beyond the subsequent diffusion
area of the skin samples. The microneedle rollers were
rolled in four axes radial [15] over the skin surface before
1 ml of the lidocaine solution in PBS was applied. Sample
withdrawal from the receptor chamber (0.4 ml) was per-
formed at predefined times with replacement by 0.4 ml
PBS. The donor chambers were covered with parafilm
(BRAND GmbH & CO KG, Wertheim, Germany).
Analysis
The receptor medium samples were analysed by high-
performance liquid chromatography utilizing a model 126
pump at 1 ml/min, a model 168 UV–VIS detector at
240 nm, and a model 507 autosampler (all Beckman,
Fullerton, CA, USA) for the injection of 100 μl. A reversed
phase HPLC column (LiChroCART 250–4, LiChrospher®
100 RP-18, 5 μm, Merck, Darmstadt, Germany) com-
bined with a guard column (LiChroCART® 4–4 mm,
LiChrospher®100 RP-18 (5 μm), Merck, Darmstadt,
Germany) were used at 40°C. The mobile phase comprises
78% phosphate buffer (pH 5.5) and 20% acetonitrile, 1%
triethylamine and 1% acetic acid degassed via sonication.
Data analysis
An automated algorithm [16] was used to calculate the
maximum flux (Jmax, μg/cm
2/h) and the apparent per-
meability coefficient (Papp, cm/h). Values from replicated
in vitro experiments (2 replicates per treatment) at the
same individual were used as average. Differences be-
tween diffusion parameters of control (PBS) and of the
chemical additives/microneedle pretreated skin samples
were evaluated using Kruskal-Wallis test followed by
Dunnett´s multiple comparison test (GraphPad Prism
4.01 Software Inc., San Diego, USA). A 0.05 significance
level was adopted.
Figure 1 Lidocaine permeation of equine skin samples after application of topical formulations containing 2 mg/ml lidocaine (mean + SEM);
* = p < 0.05; n = 6.
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Lidocaine was able to permeate through equine skin out
of all investigated formulations (Figure 1). The highest
permeation of lidocaine was observed after administra-
tion of lidocaine in pure PBS and 50% DMSO. Formula-
tions with 50% EtOH, PG, IPA and IPM/IPA diminished
the permeation rate of lidocaine.
Parameters describing the features of the different vehi-
cles on in vitro permeation of lidocaine are summarized in
Table 1. Lidocaine in PBS showed the highest maximum
flux Jmax and the shortest lagtime through equine skin
compared to EtOH, PG, IPA and IPM/IPA. Statistical sig-
nificant differences were found for Jmax and the apparent
permeability coefficients of control vs. EtOH and PG (p <
0.05). The 6 hour-recoveries of lidocaine in 50% EtOH,
PG and IPA (p < 0.01) and IPM/IPA (p < 0.05) were signifi-
cantly different from the 6 hour-recovery of lidocaine in
PBS (1.6 to 2.2-fold lower). The addition of 50% DMSOTable 1 Mean absorption parameters, Jmax, lagtime, Papp-valu
following application of different lidocaine formulations (PBS
(50% in PBS w/w) , IPM/IPA (50% in PBS w/w), DMSO (50% in P
n = 6, * = p < 0.05, ** = p < 0.01
PBS 50% EtOH 50% PG
Mean ± STD Mean ± STD Mean ± STD
Jmax (μg/cm
2/h): 11.37 ± 1.81 6.94 ± 4.53 6.44 ± 1.43
lagtime (h): 0.86 ± 1.03 1.86 ± 1.99 1.18 ± 0.95
Papp (cm/s): 1.6E-06 ± 2.5E-07 9.6E-07 ± 6.3E-07* 8.9E-07 ± 2.0E
Recovery 6 h (%): 5.1 ± 1.0 2.3 ± 1.5** 2.9 ± 2.1**
*p < 0.05, **p < 0.01.resulted in a comparable lidocaine permeation data to
lidocaine applied in pure PBS. Although the lagtimes
ranged from the mean of 0.9 hours (PBS) to 2.2 hours
(IPA), no statistical significant differences were deter-
mined. There was no statistical significance between the
different chemical additives.
The microneedle pretreatment with both needle
lengths significantly enhanced the permeation of lido-
caine (Figure 2). Both needle lengths resulted in 1.4
higher permeation rates of lidocaine compared to con-
trol (p < 0.01) with diminished lagtimes. The lagtime
was reduced from 1 hour in the untreated control skin
to 0.8 hours in the 200 μm long microneedle treated
skin samples and to 0.5 hours in the 300 μm long
microneedle treated skin samples (Table 2). The 6-hour
recoveries were approximately 1.7 fold higher in the
microneedle pretreated skin samples (p < 0.05 (200 μm)
and p < 0.01 (300 μm)).e and recovery (mean ± standard deviation, STD),
, EtOH (50% in PBS w/w), PG (50% in PBS w/w), IPA
BS w/w) containing 2 mg/ml lidocaine on equine skin;
Vehicle
50% IPA 50% IPM/IPA(50/50 v/v) 50% DMSO
Mean ± STD Mean ± STD Mean ± STD
7.28 ± 3.00 7.21 ± 2.72 12.47 ± 1.66
2.21 ± 1.21 1.48 ± 0.61 1.63 ± 0.53
-07* 1.0E-06 ± 4.2E-07 1.0E-06 ± 3.8E-07 1.7E-06 ± 2.3E-07
2.5 ± 1.5** 3.1 ± 1.5* 4.3 ± 0.5
Figure 2 Lidocaine permeation of equine skin samples after application of 2 mg/ml lidocaine in PBS (mean + SEM) on microneedle
pretreated skin samples; the microneedles were used with a needle length of 200 μm and 300 μm; * = p < 0.05; n = 6.
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Although there are many reports demonstrating that alco-
hols may act as skin permeability enhancers as solubilizing
agents with delipidisation potential [17-20], in the present
study no enhancing effect was observed for EtOH or IPA
supplementation on transdermal permeation of lidocaine.
Permeation of lidocaine, on the contrary, was diminished to
alcohol supplementation to the vehicle compared to pure
PBS which served as control. There are also various reports
about permeation enhancements of sulfoxides like DMSO
[19,21,22], which can increase lipid fluidity and promote
drug partition [23,24] or polyols like PG [17,25,26], which
are described to solvate α-keratin and occupy hydrogen
bonding sites [27,28]. IPM exhibits a direct action on the
stratum corneum, permeates into liposome bilayers and in-
creases fluidity of membranes [19,29], but even this ali-
phatic fatty acid esters diminished lidocaine permeation
through equine skin (53,54) comparable to PG. Only
DMSO supplementation to the vehicle resulted in higher
permeation rates of lidocaine compared to PG, IPA, EtOH
or IPM/IPA, but similar permeation levels to pure PBS.
Thus, the investigated chemicals show no effectiveness asTable 2 Mean absorption parameters, Jmax, lagtime, Papp-valu
following application of 2 mg/ml lidocaine in PBS on microne




2/h): 11.17 ± 4.63
lagtime (h): 1.02 ± 0.70
Papp (cm/s): 1.6E-06 ± 6.4E-07
Recovery 6 h (%): 4.3 ± 1.4
*p < 0.05, **p < 0.01.permeation enhancers for lidocaine through equine skin,
which may be due to the physicochemical nature of lido-
caine. Furthermore, species react different to permeation en-
hancers and topically applied drugs, which has been shown
e.g. for lidocaine patches in various species. 5% lidocaine
patches administered to humans, cats and dogs resulted in
measureable lidocaine concentrations in plasma of the ex-
amined species [30-33], while there was a lack of systemic
absorption of lidocaine from 5 % patches placed on horses
[13]. Furthermore, DMSO supplementation to the vehicle of
transdermal applied lidocaine onto guinea pig skin resulted
in higher transdermal permeation rates of lidocaine [34].
Interspecies differences in the success of penetration en-
hancement via chemical additives may be due to differ-
ences in skin morphology and biochemistry. Since the
main skin barrier is maintained by the stratum corneum,
its histology and lipid composition is of high importance.
Concerning various reports about interspecies differences
in these parameters [35-37], the lack of chemical penetra-
tion enhancement in the present study may be due to
differences in the skin lipid composition of horses [38]
compared with other species [37,39,40].e and recovery (mean ± standard deviation, SD),
edle pretreated equine skin; n = 6, * = p < 0.05,
th of 200 μm and 300 μm
Treatment
200 μm 300 μm
Mean ± STD Mean ± STD
15.81 ± 3.35 16.08 ± 3.93
0.79 ± 0.28 0.51 ± 0.34
2.2E-06 ± 4.7E-07** 2.2E-06 ± 5.5E-07**
7.3 ± 2.0* 7.5 ± 1.7*
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cutaneous permeation of lidocaine through equine skin,
the second part of the present study was the investiga-
tion of the impact of mechanical permeation enhancers
(microneedles) on lidocaine permeation through equine
skin. Microneedles represent mechanical permeation en-
hancers in order to overcome the main skin barrier, the
stratum corneum. This technology has been established to
perforate the skin barrier without inducing pain or bleed-
ing, as the needles are too short to stimulate the nerves
and to damage blood vessels in the dermis [41,42]. Thus,
the produced holes act as shunt ways for topically applied
drugs with low permeability. In agreement with recent
studies, microneedles enhance transdermal drug delivery
of topically applied drugs [15,43-46]. After microneedle
pretreatment, 1.7 fold higher amounts of lidocaine were
determined in the present study in the receptor fluid after
6 hours with a 1.4 fold higher apparent permeability coef-
ficient in the microneedle pretreated skin samples. Fur-
thermore, the lag-times were reduced by 23% and 50% in
dependence on the microneedle lengths. Consequently,
from the present results it can be concluded that micro-
needle pretreatment results in a rapid onset of lidocaine
action within the skin and in the organism, which is in ac-
cordance with recent studies about lidocaine-containing
microneedle products with a rapid, safe, and prolonged
local analgesic action [47,48].
Conclusion
In conclusion, the results of the present study demonstrate
significant differences in transdermal permeation of lido-
caine dissolved in various vehicles and the high potential
of microneedle pretreatment on transdermal permeation
enhancement of lidocaine through equine skin.
Clinical relevance
For the therapy of a postoperative ileus a plasma level of
lidocaine of 1-2 μg/ml plasma is necessary [49]. Since the
mean blood volume of a horse is 50 l [50], 50-100 μg lido-
caine have to be in the organism in order to gain effective
plasma levels. With the assumption of 7.5% recovery in
the blood (recovery of 300 μm long microneedles in the
acceptor chamber after 6 hours) a transdermal formula-
tion containing 0.6-1.3 mg/ml may be adequate to reach
effective plasma levels (when applied on microneedle per-
forated skin of the thorax). But therefore, several in-vivo
studies in horses have to be performed.
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